The aim of the present study was to evaluate the benefit of monitoring serum piperacillin concentrations in critically ill patients. This was an 11-month, prospective, observational study in a 30-bed Intensive Care Unit in a teaching hospital, involving 24 critically ill patients with evidence of bacterial sepsis. All patients received a 66 mg/kg intravenous bolus of piperacillin in combination with tazobactam (ratio 1:0.125) followed by continuous infusion of 200 mg/kg/24 h. The dosage was adjusted when the serum piperacillin concentration either fell below 4 the drug's minimum inhibitory concentration (MIC) for the causative agent or exceeded the toxic threshold of 150 mg/L. With the initial regimen, serum piperacillin concentrations were within the therapeutic target range in only 50.0% of patients (n = 12). This proportion increased to 75.0% (18 patients) (P = 0.006) following dosage adjustment. For patients with low initial serum piperacillin concentrations (n = 8), the percentage of time during which the concentration remained above 4 MIC (%T>4 MIC) was 7.1 ± 5.9% before dosage adjustment and 27.3 ± 8.6%
afterwards. In conclusion, in critically ill patients, monitoring and adjustment of serum piperacillin levels is required to prevent overdosing and might also help to correct underdosing, an important cause of antibiotic therapy failure.
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Introduction
Broad-spectrum -lactams are commonly used to treat severe infections (either alone or combined with other antibiotics), especially in the Intensive Care Unit (ICU) setting. The bactericidal effects of these antibiotics are mostly time-dependent. Laboratory and clinical evidence indicates that to achieve effective bactericidal levels, a serum concentration of at least 4 times the minimum inhibitory concentration (MIC) for the pathogen involved may be required [1, 2] . A related determinant of -lactam efficacy is the time during which the drug's serum concentration remains above the MIC threshold (T>MIC) [3] . Continuous infusion of these antimicrobial agents facilitates the optimisation of their pharmacodynamic profiles [4, 5] .
In ICU patients, it is more difficult to maintain stable serum antibiotic levels. Apart from the excretory impairments observed in these patients, several other phenomena can significantly alter drug distribution and/or elimination profiles [6] . Furthermore, ICU patients show great interindividual variability in their pharmacokinetic parameters [7] , which can also change quickly in response to improvements in or worsening of the Over the last decade, new modes of administration have significantly optimised the antimicrobial activity of PIP/TAZ. In several pharmacokinetic studies, continuous infusion of PIP/TAZ was superior to intermittent injection (despite the use of lower doses) [8, 9] and also appeared to be a better pharmacoeconomic option [10] . Under these supposedly optimal pharmacokinetic conditions, the objective of this study was to assess the utility of daily serum piperacillin monitoring to achieve pharmacodynamic targets associated with optimal piperacillin activity.
Patients and methods

Subjects
Study subjects were adult patients admitted to the Department of Respiratory Emergencies and Intensive Care at Lille University Medical Center (Lille, France) with various pathologies (Table 1 ). The study's main inclusion criterion was the presence of a community-or hospital-acquired infection requiring antibiotic therapy with PIP/TAZ.
Patients with known hypersensitivity/intolerance to penicillins or a previous infection with PIP/TAZ-resistant bacteria were excluded from the study.
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Target serum concentrations
Dosage adjustment was performed when the serum piperacillin concentration was below 4 MIC for the identified pathogen or >150 mg/L (defined as the toxicity threshold, based on empirical data). Above this concentration, the likelihood of neurological adverse events increased (personal data). When the pathogen was not known, the lower target value was defined as 4 the critical concentration above which all bacterial strains are 
Blood sampling
Blood samples for pharmacokinetic analysis were obtained from a peripheral venous catheter placed in the arm not used for drug infusion. Blood was collected before starting drug administration (t = 0) and 1.5 h afterwards (t = 1.5) to ensure that the bolus injection had been completed. A sample was then taken each morning at steady state until the end of the course of treatment.
Adverse events
Convulsions, changes in white blood cell count, modification of CL Cr and signs of cutaneous intolerance were monitored throughout the study.
Page 7 of 18
A c c e p t e d M a n u s c r i p t 8
Statistical analysis
A paired Student's t-test was used to check for statistical significance. (Table 1b) before antibiotic dosage adjustment and 27.3 ± 8.6% afterwards (Fig. 1 ). This significant difference (P = 0.03) demonstrates the beneficial impact of regular serum piperacillin monitoring on these important therapeutic PK/PD parameters.
Results and discussion
Conclusion
In critically ill patients, monitoring and adjustment of serum piperacillin levels are warranted to prevent overdosing and to help correct underdosing, an important cause of antibiotic therapy failure. Additional trials in a more homogeneous patient population are required to underpin these preliminary findings.
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